TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06429046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIDOCAINE GEL
Description: To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COLD LIDOCAINE GEL
Description: In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.
Study: NCT03998514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 1
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 2
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 3
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 4
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 5
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose 6
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose TBD
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose TBD
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose TBD
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB4211 Dose TBD
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT00614419

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolene Polypropylene Mesh
Description: The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Inguinal Hernia Matrix
Description: The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
Study: NCT01958255

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: planned intervention for tobacco cessation counseling
Description: game session for rapport building followed by group discussion and tobacco cessation counseling
Study: NCT02027727

Intervention type: OTHER
Intervention: No Intervention
Description: no intervention- tihs is an observational study
Study: NCT01344486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full conditioning
Description: addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pneumoperitoneum
Description: 100% carbon dioxide used for the pneumoperitoenum
Study: NCT01861561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous cyclophosphamide
Description: Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose intravenous cyclophosphamide
Description: Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose
Study: NCT03075852

Intervention type: DEVICE
Intervention: Heads- Up Display Surgery
Description: Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
Study: NCT00194467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir
Description: 900 mg once a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo, once a day for 8 weeks
Study: NCT03320837

Intervention type: DIETARY_SUPPLEMENT
Intervention: Infant formula
Description: Breast milk substitute containing synbiotics

Intervention type: DIETARY_SUPPLEMENT
Intervention: Infant formula
Description: Breast milk substitute containing synbiotics

Intervention type: OTHER
Intervention: Breast milk
Description: Breast milk

Intervention type: OTHER
Intervention: Breast milk
Description: Breast milk
Study: NCT04534400

Intervention type: RADIATION
Intervention: thoracic CT-scan
Description: Automated measurement

Intervention type: RADIATION
Intervention: thoracic CT-scan
Description: Automated measurement
Study: NCT01203722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus 1mg intravenously, daily
Study: NCT01955395

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Resiliency Program (3RP)
Description: The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Resiliency Program (3RP)
Description: The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
Study: NCT02639403

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal three-dimensional Radiotherapy
Description: Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
Study: NCT03037606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabelis DDR 50 mg Capsules
Description: Rabelis DDR 50 mg Capsules once daily for seven days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pariet 20 mg Enteric Coated Tablets
Description: Pariet 20 mg Enteric Coated Tablets once daily for seven days.
Study: NCT03406715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell based p53 Vaccine
Description: Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
Study: NCT00910728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480
Description: Oral capsule 2.5 mg, 10 mg and 40 mg
Study: NCT00578604

Intervention type: DEVICE
Intervention: diffuse near infrared spectroscopy measurements
Description: Measure blood flow to diabetic wounds

Intervention type: DEVICE
Intervention: diffuse near infrared spectroscopy measurements
Description: Measure blood flow to diabetic wounds
Study: NCT04297293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
Study: NCT04521920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study: NCT02440204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
Study: NCT04521920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP
Description: Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study: NCT00858936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-1001
Description: 6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
Study: NCT02204423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Radial Percutaneous Coronary Intervention (TR-PCI)
Study: NCT01545297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
Study: NCT00858936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
Study: NCT00611988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-managed walking
Description: The intervention includes individual therapy, group reinforcement, and follow-up phone contact
Study: NCT02956746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN023
Description: The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN023
Description: The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imovax
Description: Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax
Description: Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RabAvert
Description: Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RabAvert
Description: Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HyperRAB ST (human rabies immune globulin)
Description: The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HyperRAB ST (human rabies immune globulin)
Description: The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
Study: NCT00976105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem or placebo - Hypnotic drug given for sleep disorders
Description: The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498 or placebo
Description: The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
Study: NCT03640403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-amodiaquine
Description: Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
Study: NCT00611988

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Attention control group will receive routine follow-up phone calls
Study: NCT00756678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubricant Eye Drops (Optive™)
Description: 1 drop in both eyes as needed for 7 days'

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubricating Eye Drops (blink® Tears)
Description: 1 drop in both eyes as needed for 7 days
Study: NCT03006081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept injection
Description: Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
Study: NCT00829218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glutamate additive-free diet
Description: All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glutamate additive-free diet
Description: All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo diet
Description: Juice with nothing added.
Study: NCT01110226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KML-001
Description: KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off.
Study: NCT03554083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study: NCT04293276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 Tablets
Study: NCT02491047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BonyPid-1000
Description: BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) treatment
Description: Standard of Care (SOC) treatment only